natgillin/translations-raw huggingface dataset:
The usual dose is one tablet in the morning and one tablet in the evening.
Običajno odmerjanje je ena tableta zjutraj in ena tableta zvečer.
Marketing Authorisation Holder: Les Laboratoires Servier 50, rue Carnot
Imetnik dovoljenja za promet z zdravilom: Les Laboratoires Servier 50, rue Carnot
If you are pregnant and have taken Corlentor, talk to your doctor.
Če ste noseči in ste jemali zdravilo Corlentor, se posvetujte z zdravnikom.
The safety and efficacy of ivabradine in children aged below 18 years have not yet been established.
Varnost in učinkovitost ivabradina pri otrocih, mlajših od 18 let, še nista bili dokazani.
Luminous visual phenomena (brief moments of increased brightness, most often caused by sudden changes in light intensity).
Vidni pojavi svetlikanja (kratki trenutki povečane svetlosti, ki jih največkrat povzročajo nenadne spremembe jakosti svetlobe).
Corlentor mainly works by reducing the heart rate by a few beats per minute.
Corlentor deluje predvsem tako, da znižuje srčno frekvenco za nekaj utripov na minuto.
Corlentor should be taken during meals.
Zdravilo Corlentor morate jemati med obrokom.
Aluminium/PVC blister packed in cardboard boxes.
Pretisni omoti iz aluminija/polivinil klorida, pakirani v kartonastih škatlah.
In addition, discontinuation of treatment should be considered if there is only limited symptomatic response and when there is no clinically relevant reduction in resting heart rate within three months.
O prekinitvi zdravljenja morate razmisliti tudi, če obstaja le omejen simptomatski odziv in kadar znižanje srčne frekvence v mirovanju po 3 mesecih ni klinično pomembno.
In dogs given ivabradine (doses of 2, 7 or 24 mg/kg/day) for one year, reversible changes in retinal function were observed but were not associated with any damage to ocular structures.
Pri psih, ki so jim dajali ivabradin (v odmerkih 2, 7 ali 24 mg/kg/dan) eno leto, so opazili reverzibilne spremembe delovanja mrežnice, ki pa niso bile povezane z nobenimi poškodbami očesnih struktur.
The onset of phosphenes is generally within the first two months of treatment after which they may occur repeatedly.
Fosfeni se večinoma pojavljajo v prvih dveh mesecih zdravljenja in nato se lahko večkrat ponovijo.
They generally occur within the first two months of treatment after which they may occur repeatedly and resolve during or after treatment
Navadno se pojavijo v prvih dveh mesecih zdravljenja, nato se lahko občasno ponavljajo ter izginejo med ali po zdravljenju.
Hazard ratio [95% CI]
razmerje tveganja [95 % interval zaupanja]
Other medicines and Corlentor
Druga zdravila in zdravilo Corlentor
If there is no improvement in symptoms of angina within 3 months after start of treatment, treatment of ivabradine should be discontinued.
Če se simptomi angine pektoris ne izboljšajo po 3 mesecih od uvedbe zdravljenja, morate zdravljenje z ivabradinom prekiniti.
Do not take a double dose to make up for the forgotten dose.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjega.
Animal studies indicate that ivabradine is excreted in milk.
Študije na živalih kažejo, da se ivabradin izloča v materino mleko.
Hypertensive patients requiring blood pressure treatment modifications.
Bolniki s hipertenzijo, ki potrebujejo spremembo zdravljenja zvišanega krvnega tlaka
These trials included a total of 4,111 patients with chronic stable angina pectoris, of whom 2,617 received ivabradine.
Skupno so zajele 4111 bolnikov s kronično stabilno angino pektoris, od katerih jih je 2617 jemalo ivabradin.
Stable angina is a heart disease which happens when the heart does not receive enough oxygen.
Stabilna angina pektoris je bolezen srca, ki nastaja, ko srce ne dobiva dovolj kisika.
Patients should be informed of signs and symptoms of atrial fibrillation and be advised to contact their physician if these occur.
Bolnike morate obvestiti o znakih in simptomih atrijske fibrilacije in jim svetovati, da v primeru njihovega pojava za pomoč prosijo svojega zdravnika.
There is no evidence of risk of (excessive) bradycardia on return to sinus rhythm when pharmacological cardioversion is initiated in patients treated with ivabradine.
Ni dokazov o tveganju (prevelike) bradikardije ob vrnitvi na sinusni ritem pri sprožanju farmakološke kardioverzije pri bolnikih, ki jemljejo ivabradin.
A drug utilisation study conducted in several EEA countries aimed at describing the characteristics of ivabradine users, as well as describing the patterns of use of ivabradine, and adherence to the risk minimisation measures.
Namen študije uporabe zdravila, v katero je vključeno več držav Evropskega gospodarskega prostora, je opisati značilnosti uporabnikov ivabradina, kakor tudi način uporabe ivabradina in upoštevanje ukrepov za zmanjševanje tveganja.
What Corlentor is and what it is used for What you need to know before you take Corlentor How to take Corlentor
Kaj je zdravilo Corlentor in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Corlentor Kako jemati zdravilo Corlentor
Calendar packs containing 14, 28, 56, 84, 98, 100 or 112 film-coated tablets.
Koledarska pakiranja, ki vsebujejo 14, 28, 56, 84, 98, 100 ali 112 filmsko obloženih tablet.
Your doctor will decide the right dose for you.
Pravi odmerek za vas bo določil zdravnik.
Chronic heart failure is a heart disease which happens when your heart cannot pump enough blood to the rest of your body.
Kronično srčno popuščanje je srčna bolezen, ki se pojavi, ko srce ne zmore črpati zadostne količine krvi ostalim delom telesa.
Concomitant use not recommended
Sočasno jemanje ni priporočljivo
Pharmacokinetic/pharmacodynamic (PK/PD) relationship
Farmakokinetično/farmakodinamično (PK/PD) razmerje
No data are available in patients with creatinine clearance below 15 ml/min.
Za bolnike z očistkom kreatinina pod 15 ml/min ni podatkov.
The frequency of possible side effects listed below is defined using the following convention: very common: may affect more than 1 in 10 people common: may affect up to 1 in 10 people uncommon: may affect up to 1 in 100 people rare: may affect up to 1 in 1,000 people very rare: may affect up to 1 in 10,000 people not known: frequency cannot be estimated from the available data
Pogostnost možnih spodaj navedenih neželenih učinkov je definirana z uporabo naslednjega dogovora: zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov občasni: pojavijo se lahko pri največ 1 od 100 bolnikov redki: pojavijo se lahko pri največ 1 od 1.000 bolnikov zelo redki: pojavijo se lahko pri največ 1 od 10.000 bolnikov neznana pogostnost: pogostnosti iz razpoložljivih podatkov ni mogoče oceniti
Phosphenes were generally reported to be of mild to moderate intensity.
Fosfeni so bili na splošno blage do zmerne jakosti.
In this subgroup of patients, the safety profile of ivabradine is in line with the one of the overall population.
Pri tej skupini bolnikov je bil varnostni profil ivabradina v skladu s tistim pri celotni populaciji bolnikov.
If you still have angina symptoms and if you have tolerated the 5 mg twice daily dose well, the dose may be increased.
Če imate še vedno prisotne simptome angine pektoris in če dobro prenašate 5 mg zdravila dvakrat na dan, se odmerek lahko poveča.
Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightness in a limited area of the visual field.
O pojavih svetlikanja (fosfenih) so poročali pri 14,5 % bolnikov, opisujejo pa jih kot prehodno povečanje svetlosti na omejenem področju vidnega polja.
Ivabradine 5 mg twice daily was shown to be effective on exercise test parameters within 3 to 4 weeks of treatment.
Ivabradin 5 mg dvakrat na dan je bil dokazano učinkovit glede parametrov obremenitvenega testa po 3 do 4 tednih zdravljenja.
If atrial fibrillation develops during treatment, the balance of benefits and risks of continued ivabradine treatment should be carefully reconsidered.
Če se atrijska fibrilacija razvije med zdravljenjem, morate pazljivo pretehtati ravnovesje med koristmi in tveganji nadaljnjega zdravljenja z ivabradinom.
At higher doses, the decrease in heart rate is no longer proportional to ivabradine plasma concentrations and tends to reach a plateau.
Ob večjih odmerkih znižanje srčne frekvence ni več sorazmerno s koncentracijo ivabradina v plazmi in kaže težnjo k doseganju platoja.
Les Laboratoires Servier Industrie 905 route de Saran 45520 Gidy - France
Les Laboratoires Servier Industrie 905 route de Saran 45520 Gidy - Francija
Bradycardia was reported by 17.9 % of patients in the ivabradine group (2.1% in the placebo group).
O bradikardiji so poročali pri 17,9 % bolnikov, ki so jemali ivabradin (2,1 % bolnikov iz skupine, ki je prejemala placebo).
The treatment has to be initiated only in patient with stable heart failure.
Zdravljenje lahko začnete le pri bolnikih s stabilnim srčnim popuščanjem.
In this study, the antianginal and anti-ischaemic benefits of ivabradine were confirmed in patients aged 65 years or more.
V tej študiji so antianginozni in antiishemični učinek ivabradina potrdili pri bolnikih, starih 65 ali več let.
If any of the above applies to you, talk straight away to your doctor before or while taking Corlentor.
Če karkoli od naštetega velja za vas, se takoj pogovorite z zdravnikom pred jemanjem zdravila Corlentor ali med njim.
Angina is more likely to happen when the heart beats faster in situations such as exercise, emotion, exposure to the cold or after eating.
Angina pektoris se verjetneje pojavlja v položajih, kadar srce utripa hitreje, na primer med vadbo, ob razburjenosti, izpostavljenosti mrazu ali po jedi.
They can also be described as a halo, coloured flashes, image decomposition or multiple images.
Lahko jih opišemo tudi kot svetle kolobarje, obarvane bliske, razgradnjo slike ali pomnožene slike.
To date, there is no evidence of a toxic effect of ivabradine on the retina, but the effects of long-term ivabradine treatment beyond one year on retinal function are currently not known.
Do danes niso opazili, da bi ivabradin imel toksičen učinek na mrežnico, toda zaenkrat še ne poznamo učinkov dolgoročnega zdravljenja z ivabradinom, daljšega od 1 leta, na delovanje mrežnice.
Ivabradine is eliminated with a main half-life of 2 hours (70-75% of the AUC) in plasma and an effective half-life of 11 hours.
Ivabradin se izloča z glavno razpolovno dobo 2 uri (70 do 75 % površine pod krivuljo (AUC)) v plazmi in efektivno razpolovno dobo 11 ur.
The tablets are available in calendar packs (Aluminium/PVC blisters) of 14, 28, 56, 84, 98, 100 or 112 tablets.
Tablete so na voljo v koledarskih pakiranjih (pretisnih omotih Alu/PVC), ki vsebujejo 14, 28, 56, 84, 98, 100 ali 112 tablet.
It is recommended that the treating physician should be experienced in the management of chronic heart failure.
Priporočljivo je, da je lečeči zdravnik izkušen v zdravljenju kroničnega srčnega popuščanja.
The European Medicines Agency has deferred the obligation to submit the results of studies with Corlentor in one or more subsets of the paediatric population in the treatment of chronic heart failure (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom Corlentor za eno ali več podskupin pediatrične populacije za zdravljenje kroničnega srčnega popuščanja (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
How does Corlentor work?
Kako deluje zdravilo Corlentor?
Ivabradine is contra-indicated in patients with severe hypotension (blood pressure < 90/50 mmHg) (see section 4.3).
Ivabradin je kontraindiciran pri bolnikih s hudo hipotenzijo (krvnim tlakom < 90/50 mm Hg) (glejte poglavje 4.3).
The most common adverse reactions with ivabradine, luminous phenomena (phosphenes) and bradycardia, are dose dependent and related to the pharmacological effect of the medicinal product.
Najpogostnejši neželeni učinki ob ivabradinu, pojavi svetlikanja (fosfeni) in bradikardija, so odvisni od odmerka in povezani s farmakološkim delovanjem zdravila.
Corlentor may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see “Possible side effects”).
Corlentor lahko povzroča začasne vidne pojave svetlikanja (prehodno povečanje svetlosti v vidnem polju, glejte “Možni neželeni učinki”).
If you forget to take Corlentor
Če ste pozabili vzeti zdravilo Corlentor
The starting dose of ivabradine should not exceed 5 mg twice daily in patients aged below 75 years.
Začetni odmerek ivabradina ne sme presegati 5 mg dvakrat na dan pri bolnikih, mlajših od 75 let.
Pharmacotherapeutic group: Cardiac therapy, other cardiac preparations, ATC code: C01EB17.
Farmakoterapevtska skupina: zdravila za bolezni srca, druga zdravila za bolezni srca, oznaka ATC: C01EB17
Excretion of metabolites occurs to a similar extent via faeces and urine.
Izločanje presnovkov poteka v podobnem obsegu s fecesom in urinom.
LIST OF EXCIPIENTS Contains lactose monohydrate.
SEZNAM POMOŽNIH SNOVI Zdravilo vsebuje laktozo monohidrat.
Phosphenes may also be described as a halo, image decomposition (stroboscopic or kaleidoscopic effects), coloured bright lights, or multiple image (retinal persistency).
Fosfene lahko opišemo tudi kot svetle kolobarje, razgradnje slike (stroboskopski ali kalejdoskopski učinki), obarvane svetle luči ali pomnožene slike (vztrajnost mrežnice).
Atrial fibrillation - Cardiac arrhythmias
Atrijska fibrilacija - srčne aritmije
There was no evidence of pharmacological tolerance (loss of efficacy) developing during treatment nor of rebound phenomena after abrupt treatment discontinuation.
Ni bilo dokazov, da bi med zdravljenjem nastajala farmakološka toleranca (zmanjšanje učinkovitosti) ali o povratnem učinku po nenadni prekinitvi zdravljenja.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.
podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP.
If you are being treated for stable angina pectoris
Če se zdravite zaradi stabilne angine pektoris
The antianginal and anti-ischaemic efficacy of ivabradine was studied in five double-blind randomised trials (three versus placebo, and one each versus atenolol and amlodipine).
Antianginozno in antiishemično učinkovitost ivabradina so proučevali v petih dvojno slepih randomiziranih študijah (treh v primerjavi s placebom ter po eni z atenololom in amlodipinom).
Ivabradine efficacy was fully maintained throughout the 3- or 4-month treatment periods in the efficacy trials.
Učinkovitost ivabradina se je v študijah o učinkovitosti v celoti ohranjala med 3- ali 4-mesečnim zdravljenjem.
Grapefruit juice: ivabradine exposure was increased by 2-fold following the co-administration with grapefruit juice.
Grenivkin sok: izpostavljenost ivabradinu se je 2-kratno povečala po sočasnem jemanju z grenivkinim sokom.
This also applies to patients with a low heart rate, in particular when heart rate decreases below 50 bpm, or after dose reduction (see section 4.2).
To velja tudi za bolnike z nizko srčno frekvenco, zlasti kadar se srčna frekvenca zniža pod 50 utripov na minuto, ali po zmanjšanju odmerka (glejte poglavje 4.2).
The use of ivabradine is not recommended immediately after a stroke since no data is available in these situations.
Jemanje ivabradina takoj po možganski kapi ni priporočljivo, ker ni podatkov o tovrstnih stanjih.
The most common symptom of angina is chest pain or discomfort.
Najpogostnejši simptom angine pektoris je bolečina ali neugodje v prsih.
No influence on glucose or lipid metabolism was observed.
Vpliva na presnovo glukoze ali lipidov niso opazili.
Severe bradycardia should be treated symptomatically in a specialised environment.
Bolnike s hudo bradikardijo morate zdraviti simptomatsko v specializiranem okolju.
The Ndesmethylated derivative of ivabradine has been identified as the main active metabolite in humans.
N-demetilirani derivat ivabradina so določili kot poglavitni aktivni presnovek pri ljudeh.
No data are available in patients with severe hepatic impairment (see sections 4.2 and 4.3).
O bolnikih s hudim jetrnim popuščanjem podatkov ni (glejte poglavji 4.2 in 4.3).
Ivabradine is therefore not recommended in patients with atrial fibrillation or other cardiac arrhythmias that interfere with sinus node function.
Ivabradin torej ni priporočljiv pri bolnikih z atrijsko fibrilacijo ali drugimi srčnimi aritmijami, ki motijo delovanje sinusnega vozla.
Temporary cardiac electrical pacing may be instituted if required.
Če je potrebno, lahko uvedete začasno električno spodbujanje srca.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Če vam je zdravnik povedal, da ne prenašate določenih vrst sladkorja, se posvetujte z njim, preden vzamete to zdravilo.
Symptoms Overdose may lead to severe and prolonged bradycardia (see section 4.8).
Preveliko odmerjanje lahko privede do hude in podaljšane bradikardije (glejte poglavje 4.8).
The efficacy of 5 and 7.5 mg twice daily was consistent across studies on exercise test parameters (total exercise duration, time to limiting angina, time to angina onset and time to 1 mm ST segment depression) and was associated with a decrease of about 70% in the rate of angina attacks.
Učinkovitost odmerkov 5 mg in 7,5 mg dvakrat na dan glede parametrov obremenitvenega testa (skupnega trajanja vadbe, časa do omejujoče angine, časa do nastopa angine in časa do 1-mm depresije segmenta ST) je bila dosledna v vseh študijah ter povezana z zmanjšanjem števila anginoznih napadov za približno 70 %.
Reproductive toxicity studies showed no effect of ivabradine on fertility in male and female rats.
Študije o vplivu na sposobnost razmnoževanja niso pokazale učinka ivabradina na plodnost pri samcih in samicah podgan.
Under triggering circumstances (e.g. rapid changes in luminosity), partial inhibition of Ih by ivabradine underlies the luminous phenomena that may be occasionally experienced by patients.
V sprožilnih okoliščinah (na primer ob hitrih spremembah svetlosti) je delno zaviranje Ih ob ivabradinu osnova za pojave svetlikanja, ki jih lahko občasno opažajo bolniki.
If the combination appears necessary, close cardiac monitoring is needed (see section 4.4).
Če se kombinacija zdi potrebna, morate pozorno spremljati srce (glejte poglavje 4.4).
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJE
Limited data are available in patients with mild to moderate hypotension, and ivabradine should therefore be used with caution in these patients.
Podatki pri bolnikih z blago do zmerno hipotenzijo so omejeni, zato morate pri njih ivabradin uporabljati previdno.
Efficacy was confirmed with 7.5 mg twice daily.
Učinkovitost so potrdili z odmerkom 7,5 mg na dan.
Women of child-bearing potential should use appropriate contraceptive measures during treatment (see section 4.3).
Ženske v rodni dobi morajo v času zdravljenja uporabljati zanesljive kontracepcijske metode (glejte poglavje 4.3).
They are usually triggered by sudden variations in light intensity.
Običajno jih sprožajo nenadna nihanja jakosti svetlobe.
Drug-drug interaction studies have established that CYP3A4 inhibitors increase ivabradine plasma concentrations, while inducers decrease them.
Študije o medsebojnih delovanjih z zdravili so pokazale, da zaviralci citokroma P450 3A4 povečujejo koncentracijo ivabradina v plazmi, medtem ko jo spodbujevalci zmanjšujejo.
When pregnant animals were treated during organogenesis at exposures close to therapeutic doses, there was a higher incidence of foetuses with cardiac defects in the rat and a small number of foetuses with ectrodactylia in the rabbit.
Ko so breje živali zdravili med organogenezo pri izpostavljenostih, ki so bile blizu terapevtskim odmerkom, so opazili večjo pojavnost fetusov s srčnimi napakami pri podganah in majhno število fetusov z ektrodaktilijo pri zajcih.
The difference in heart rate between ivabradine and placebo arms was 10.8 bpm at 28 days, 9.1 bpm at 12 months and 8.3 bpm at 24 months.
Razlika v srčni frekvenci med skupino z ivabradinom in skupino s placebom je bila 10,8 utripov na minuto v 28 dneh, 9,1 utripov na minuto v 12 mesecih in 8,3 utripov na minuto v 24 mesecih.
There are no or limited amount of data from the use of ivabradine in pregnant women.
Podatkov o uporabi ivabradina pri nosečnicah ni oziroma so omejeni.
Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field (see section 4.8).
Pojave svetlikanja (fosfene) opisujejo kot prehodno povečanje svetlosti na omejenem področju vidnega polja (glejte poglavje 4.8).
The potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily) increased ivabradine mean plasma exposure by 7 to 8 fold.
Močna zaviralca citokroma P450 3A4 ketokonazol (200 mg enkrat na dan) in josamicin (1 g dvakrat na dan) sta povečala srednjo izpostavljenost ivabradinu v plazmi za 7- do 8-krat.
The main efficacy criterion was the composite of cardiovascular death, hospitalization for acute MI or hospitalization for new onset or worsening heart failure.
Poglavitno merilo učinkovitosti je bil sestavljen izid srčno-žilne umrljivosti, hospitalizacije zaradi akutnega miokardnega infarkta in hospitalizacije zaradi novonastalega srčnega popuščanja ali njegovega poslabšanja.
The intake of the tablet during meals is recommended in order to decrease intra-individual variability in exposure (see section 4.2).
Priporočljivo je jemanje tablet v času obrokov za zmanjšanje nihanj v izpostavljenosti med posameznimi bolniki (glejte poglavje 4.2).
Additional efficacy of ivabradine in combination with dihydropyridine calcium channel blockers has not been established (see section 5.1).
Dodatne učinkovitosti ivabradina v kombinaciji z dihidropiridinskimi kalcijevimi antagonisti niso zasledili (glejte poglavje 5.1).
These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarisation-activated Ih currents in the retina, which share extensive homology with the cardiac pacemaker If current.
Ti podatki so skladni s farmakološkim učinkom ivabradina, povezanim z njegovim medsebojnim delovanjem z mrežničnimi hiperpolarizacijsko sproženimi tokovi Ih, ki si delijo obširno homologijo s srčnim frekvenčno urejevalnim tokom If.
However, in the absence of extensive data, non urgent DC-cardioversion should be considered 24 hours after the last dose of ivabradine.
Toda ker ni obsežnejših podatkov, razmislite o neurgentni kardioverziji z enosmernim tokom v 24 urah po zadnjem odmerku ivabradina.
Preferred Term
Sprejeti izraz
The main pharmacodynamic property of ivabradine in humans is a specific dose dependent reduction in heart rate.
Poglavitna farmakološka lastnost ivabradina pri ljudeh je specifično od odmerka odvisno zniževanje srčne frekvence.
There was a significant improvement in NYHA class at last recorded value, 887 (28%) of patients on ivabradine improved versus 776 (24%) of patients on placebo (p=0.001).
Pri razredu NYHA v zadnji zabeleženi vrednosti je bilo značilno izboljšanje, 887 (28 %) bolnikom zdravljenih z ivabradinom se je stanje izboljšalo v primerjavi z izboljšanjem pri 776 (24 %) bolnikov, ki je prejemalo placebo (p=0,001).
In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Corlentor 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening.
Nekaterim bolnikom (na primer, če ste starejši) lahko zdravnik predpiše polovični odmerek, se pravi eno polovico 5 mg tablete (kar ustreza 2,5 mg ivabradina) zjutraj in eno polovico 5 mg tablete zvečer.